TaiGen Biopharmaceuticals Holdings Limited

Equities

4157

KYG866171005

Biotechnology & Medical Research

End-of-day quote Taipei Exchange 07:00:00 2024-03-27 pm EDT 5-day change 1st Jan Change
15.45 TWD 0.00% Intraday chart for TaiGen Biopharmaceuticals Holdings Limited +5.10% +1.64%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
TaiGen Biopharmaceuticals Holdings Limited Reports Earnings Results for the Full Year Ended December 31, 2023 CI
TaiGen Biopharmaceuticals Holdings Limited Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
TaiGen Biopharmaceuticals Holdings Limited Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
TaiGen Biopharmaceuticals Holdings Limited Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
TaiGen Biopharmaceuticals Holdings Limited Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022 CI
TaiGen Biopharmaceuticals Holdings Limited Reports Earnings Results for the First Quarter Ended March 31, 2022 CI
TaiGen Biopharmaceuticals Holdings Limited Reports Earnings Results for the Full Year Ended December 31, 2021 CI
TaiGen Biopharmaceuticals Turns to Profit in 2021 MT
TaiGen Biopharmaceuticals Holdings Limited Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021 CI
Taigen Biopharmaceuticals Holdings Limited Reports Earnings Results for the Second Quarter Ended June 30, 2021 CI
Taigen Biopharmaceuticals Holdings Limited Reports Earnings Results for the First Quarter Ended March 31, 2021 CI
Taigen Biopharmaceuticals Holdings Limited Reports Earnings Results for the Full Year Ended December 31, 2020 CI
TaiGen Biotechnology Company, Limited Partners with GPCR Therapeutics, Inc. to Develop Burixafor & Taigexyn(R) CI
Taigen Biopharmaceuticals Holdings Limited Reports Earnings Results for the Third Quarter Ended September 30, 2020 CI
Taigen Biopharmaceuticals Holdings Limited Reports Earnings Results for the Second Quarter Ended June 30, 2020 CI
Taigen Biopharmaceuticals Holdings Limited Reports Earnings Results for the First Quarter Ended March 31, 2020 CI
Taigen Biopharmaceuticals Holdings Limited Reports Earnings Results for the Full Year Ended December 31, 2019 CI
Taigen Biopharmaceuticals Holdings Limited Reports Earnings Results for the Third Quarter Ended September 30, 2019 CI
Taigen Biopharmaceuticals Holdings Limited Reports Earnings Results for the Second Quarter Ended June 30, 2019 CI
Taigen Biopharmaceuticals Holdings Limited Reports Earnings Results for the First Quarter Ended March 31, 2019 CI
Taigen Biopharmaceuticals Holdings Limited Reports Earnings Results for the Full Year Ended December 31, 2018 CI
Taigen Biopharmaceuticals Holdings Limited Reports Earnings Results for the Third Quarter Ended September 30, 2018 CI
Chart TaiGen Biopharmaceuticals Holdings Limited
More charts
TAIGEN BIOPHARMACEUTICALS HOLDINGS LIMITED is a Taiwan-based company principally engaged in the research and production of pharmaceutical products. The Company's products mainly are new chemical entities (NCEs) in infectious diseases, cancer and diabetes-related complications. Its products include Nemonoxacin, Burlxafor and TG-2349. The Company receives its revenue mainly from the authorization of Nemonoxacin products.
More about the company